GILD - Gilead Sciences, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
74.84
-2.47 (-3.19%)
At close: 4:00PM EDT

74.99 +0.15 (0.20%)
Pre-Market: 4:03AM EDT

Stock chart is not supported by your current browser
Previous Close77.31
Open76.40
Bid74.81 x 1300
Ask75.55 x 2900
Day's Range74.25 - 76.47
52 Week Range64.27 - 89.54
Volume11,006,669
Avg. Volume6,639,718
Market Cap97.018B
Beta1.45
PE Ratio (TTM)44.71
EPS (TTM)1.67
Earnings DateOct 24, 2018 - Oct 29, 2018
Forward Dividend & Yield2.28 (2.93%)
Ex-Dividend Date2018-09-13
1y Target Est87.87
Trade prices are not sourced from all markets
  • Long-acting injection a shot in the arm for GSK's HIV business
    Reuters18 hours ago

    Long-acting injection a shot in the arm for GSK's HIV business

    A long-acting injection developed by GlaxoSmithKline and given once a month has proved as effective as standard daily pills for controlling the AIDS virus, lifting prospects for the British drugmaker's key HIV business. GSK's majority-owned ViiV Healthcare unit said on Wednesday the experimental two-drug injection of cabotegravir and rilpivirine maintained similar rates of viral suppression compared with a standard three-drug oral regimen, after 48 weeks of a clinical trial. GSK hopes its new approach will allow it to compete more effectively against Gilead Sciences, the U.S. drugmaker that dominates the $26 billion-a-year HIV market.

  • Long-acting injection a shot in the arm for GSK's HIV business
    Reuters21 hours ago

    Long-acting injection a shot in the arm for GSK's HIV business

    A long-acting injection developed by GlaxoSmithKline and given once a month has proved as effective as standard daily pills for controlling the AIDS virus, lifting prospects for the British drugmaker's key HIV business. GSK's majority-owned ViiV Healthcare unit said on Wednesday the experimental two-drug injection of cabotegravir and rilpivirine maintained similar rates of viral suppression compared with a standard three-drug oral regimen, after 48 weeks of a clinical trial. GSK hopes its new approach will allow it to compete more effectively against Gilead Sciences, the U.S. drugmaker that dominates the $26 billion-a-year HIV market.

  • Reutersyesterday

    Congo deploys experimental Ebola treatment as cases rise

    GOMA, Democratic Republic of Congo/GENEVA, Aug 14 (Reuters) - D emocratic Republic of Congo has started using the experimental mAb114 Ebola treatment to counter the latest flare-up of the virus, health officials said on Tuesday, the first time it has been deployed against an active outbreak. Forty-two people are believed to have died from the haemorrhagic fever in Congo's tenth Ebola outbreak since it was discovered in the 1970s. In all, there have been 66 cases to date, including 39 confirmed and 27 probable, the health ministry said on Tuesday evening, an increase of nine confirmed cases since Monday.

  • After five months on job, Gilead chief medical officer joins exodus
    American City Business Journals2 days ago

    After five months on job, Gilead chief medical officer joins exodus

    Dr. Andrew Cheng, appointed in March as chief medical officer of Gilead Sciences Inc., is leaving the company, joining an exodus of top-level executives from the Foster City-based drug developer. Cheng will "pursue another opportunity," Gilead (NASDAQ: GILD) said Tuesday while disclosing two promotions. Dr. Diana Brainard was promoted from vice president of clinical research, to senior vice president of HIV and emerging viral infections, and Gregg Alton, executive vice president of corporate and medical affairs, will become Gilead's first chief patient officer.

  • Business Wire2 days ago

    Gilead Sciences Announces Executive Promotions

    Gilead Sciences, Inc. (GILD) today announced that Gregg Alton has been appointed Chief Patient Officer, a newly created role that will facilitate access to the company’s medicines and increase focus on reaching patients. The company also announced that Diana Brainard, MD, has been promoted to Senior Vice President, HIV and Emerging Viral Infections, and that Andrew Cheng, MD, PhD, Chief Medical Officer, has decided to leave Gilead to pursue another opportunity.

  • Shire, Shionogi File NDA for Intuniv for Adults in Japan
    Zacks3 days ago

    Shire, Shionogi File NDA for Intuniv for Adults in Japan

    Shire's (SHPG) Japanese partner Shionogi & Co., Ltd submits a new drug application for Intuniv in Japan for the treatment of attention deficit hyperactivity disorder (ADHD) in adults.

  • Amicus (FOLD) Gets FDA Nod for Fabry Disease Drug Galafold
    Zacks3 days ago

    Amicus (FOLD) Gets FDA Nod for Fabry Disease Drug Galafold

    Amicus (FOLD) gets a major boost with the FDA approval of lead candidate, Galafold (migalastat) 123 mg capsules for the treatment of Fabry disease.

  • Biotech ETFs in Focus on String of Q2 Earnings Beat
    Zacks6 days ago

    Biotech ETFs in Focus on String of Q2 Earnings Beat

    Biotech ETFs draw attention post impressive Q2 results.

  • Investopedia6 days ago

    Gilead Sciences Seen Rising 13% on Better Outlook

    Gilead Sciences Inc. ( GILD) has risen by more than 18% since the start of May, and it looks likes shares may still be heading even higher. Analysts have been upping their earnings and revenue outlook for the biotech company since it reported blowout second-quarter results at the end of July, and now see the stock rising by nearly 13% based on the average price targets. Analysts have increased their average price on the stock to $87.40 since the company reported results, up from a prior target of $85.84.

  • InvestorPlace6 days ago

    You Better Be Careful with Merck Stock, Especially at These Highs

    Health care stocks including pharmaceutical giant Merck (NYSE:MRK) have gone on a nice run of late. Merk stock has gained over 20% just since early April, touching an all-time high this week. Q1 earnings that month seemed mixed, but the market reacted positively, and Merck raised guidance in the Q2 report late last month.

  • Agenus' (AGEN) Q2 Loss Narrower Than Expected, Revenues Beat
    Zacks6 days ago

    Agenus' (AGEN) Q2 Loss Narrower Than Expected, Revenues Beat

    Agenus (AGEN) posts narrower-than-expected loss in the second quarter of 2018 and expects to file three investigational new drugs by the end of 2018.

  • Sangamo Therapeutics Rose despite Q2 Sales Miss, Higher Losses
    Market Realist7 days ago

    Sangamo Therapeutics Rose despite Q2 Sales Miss, Higher Losses

    Sangamo Therapeutics reported second-quarter sales of $21.42 million, which just missed analysts’ estimate of $21.44 million in sales. This study evaluates SB-525 gene therapy for the treatment of hemophilia A. However, SGMO’s net loss declined on a sequential basis, and the company reported solid YoY (year-over-year) sales growth. Sangamo Therapeutics’ (SGMO) sales have risen ~160.0% on a YoY basis.

  • BeiGene’s Q2 2018 Earnings: Reports Revenue Growth
    Market Realist7 days ago

    BeiGene’s Q2 2018 Earnings: Reports Revenue Growth

    BeiGene (BGNE) released its second-quarter earnings on August 9. The company surpassed Wall Street analysts’ estimates for revenues but missed its EPS estimates. BeiGene reported adjusted EPS of -$2.92 on revenues of $52.8 million, compared to its estimated EPS of -$2.06 on revenues of $22.5 million. The chart below compares BeiGene’s revenues and EPS since the first quarter of 2017.

  • Here’s How Exelixis Is Financially Positioned Now
    Market Realist7 days ago

    Here’s How Exelixis Is Financially Positioned Now

    Exelixis (EXEL) generated net revenues of $186.1 million in the second quarter of 2018 compared to $99 million in the second quarter of 2017. In the first half of 2018, Exelixis reported revenues of $399.8 million compared to $179.9 million in the first half of 2017. In the first half of 2018, Exelixis generated revenues of $280.1 million, reflecting ~92% YoY (year-over-year) growth.

  • PDL BioPharma (PDLI) Q2 Earnings Top, Revenues Slump Y/Y
    Zacks7 days ago

    PDL BioPharma (PDLI) Q2 Earnings Top, Revenues Slump Y/Y

    PDL BioPharma's (PDLI) earnings trump estimates in Q2. Lower royalties and license fees cause a significant decline in year-over-year revenues.

  • Is Crispr Therapeutics Stock Grossly Overvalued?
    Motley Fool7 days ago

    Is Crispr Therapeutics Stock Grossly Overvalued?

    Crispr's stock has started to lose momentum after blasting higher earlier this year. Is the market correcting a prior mistake, or is this dip a buying opportunity?

  • Aerie (AERI) Earnings Miss in Q2, Rhopressa Performs Well
    Zacks7 days ago

    Aerie (AERI) Earnings Miss in Q2, Rhopressa Performs Well

    Aerie's (AERI) Q2 loss is wider than expected on account of higher expenses. Nevertheless, Rhopressa's sales beat estimates as demand picks up.

  • Horizon Pharma (HZNP) Q2 Earnings & Sales Beat, Shares Rise
    Zacks7 days ago

    Horizon Pharma (HZNP) Q2 Earnings & Sales Beat, Shares Rise

    Horizon Pharma (HZNP) beat earnings and sales estimates in the second quarter of 2018.

  • What Analysts Recommend for Ionis after Q2 2018
    Market Realist7 days ago

    What Analysts Recommend for Ionis after Q2 2018

    Wall Street analysts estimate Ionis Pharmaceuticals (IONS) will report year-over-year growth of ~34.8% in revenues to $612.5 million in 2018 as compared to revenues of $507.7 million during 2017. Also, the company is estimated to report a net adjusted loss of $29.9 million during 2018 as compared to a net adjusted loss of $5.9 million during 2017, following the increase in selling, general, and administrative expenses as well as research and development expenses. The adjusted earnings per share for 2018 are estimated to come in at -$0.08 per share.

  • 3 Top Biotech Stocks to Buy in August
    Motley Fool8 days ago

    3 Top Biotech Stocks to Buy in August

    It could be the perfect time to add shares in these biotech companies to portfolios ahead of key catalysts.

  • Backed with $140M, startup launches three-pronged attack on liver diseases
    American City Business Journals8 days ago

    Backed with $140M, startup launches three-pronged attack on liver diseases

    Startup factory Third Rock Ventures is launching a three-pronged attack on liver diseases with $140 million and an unusually early and large assist from a Japanese drug maker.

  • Novo Nordisk (NVO) Beats Q2 Earnings and Sales Estimates
    Zacks8 days ago

    Novo Nordisk (NVO) Beats Q2 Earnings and Sales Estimates

    Novo Nordisk (NVO) beats earnings and sales estimates in the second quarter of 2018. Majority of sales growth originated from drugs like Victoza , Ozempic , Xultophy and Saxenda.

  • VIVUS (VVUS) Q2 Loss Wider Than Expected, Revenues Up Y/Y
    Zacks8 days ago

    VIVUS (VVUS) Q2 Loss Wider Than Expected, Revenues Up Y/Y

    VIVUS (VVUS) reports wider-than-expected loss in the second quarter. However, sales increased year over year.

  • Better Buy: Gilead Sciences, Inc. vs. Amgen Inc.
    Motley Fool8 days ago

    Better Buy: Gilead Sciences, Inc. vs. Amgen Inc.

    Which of these dividend-paying biotech stocks is the better pick right now?

  • Prothena (PRTA) Q2 Earnings Lag Estimates, Pipeline in Focus
    Zacks8 days ago

    Prothena (PRTA) Q2 Earnings Lag Estimates, Pipeline in Focus

    Prothena (PRTA) posts wider-than-expected loss in the second quarter. With the failure of lead drug, NEOD001, the focus is now mainly on its mid-stage candidate, prasinezumab.